Chase Investment Counsel’s Integra LifeSciences IART Stock Holding History

Chase Investment Counsel’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-8,525	Closed	-$549K	–	97
2018 Q2	$549K	Sell	8,525 -250	-3%	-$15.5K	0.3%	59
2018 Q1	$485K	Buy	+8,775	New	+$460K	0.25%	64
2015 Q2	–	Sell	-66,091	Closed	-$1.67M	–	100
2015 Q1	$1.67M	Sell	66,091 -4,111	-6%	-$97.2K	0.58%	49
2014 Q4	$1.56M	Sell	70,202 -2,691	-4%	-$54.6K	0.55%	56
2014 Q3	$1.48M	Buy	+72,893	New	+$1.45M	0.53%	69

Other funds holding IART

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Chase Investment Counsel's IART Position: Q3 2018 in Review

Chase Investment Counsel sold out of Integra LifeSciences (IART) in Q3 2018, closing a stake of 8,525 shares — an estimated $549K sold.

Chase Investment Counsel first reported a position in IART in Q3 2014 and held it in 5 quarters. The position peaked at $1.67M in Q1 2015. 249 funds tracked by Wall St. Rank hold IART as of Q3 2018.

Chase Investment Counsel reported no remaining Integra LifeSciences position as of Q3 2018 after selling out during the quarter.
Chase Investment Counsel sold 8,525 Integra LifeSciences shares in Q3 2018, an estimated $549K.
Chase Investment Counsel first reported a position in Integra LifeSciences in Q3 2014 and held it in 5 quarters.
Chase Investment Counsel's Integra LifeSciences position peaked at $1.67M in Q1 2015.
249 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2018.

Based on Chase Investment Counsel's 13F filing for Q3 2018, filed 1 Nov 2018.